晚期肺腺癌患者分子靶向治疗的研究进展  

Advances in Molecular Targeted Therapy for Advanced Lung Adenocarcinoma

作　　者：杨硕 陈正贤 YANG Shuo;CHEN Zhengxian(Department of Pneumology,Foresea Life Insurance Guangzhou General Hospital,Guangzhou,Guangdong 511300,China;The sixth affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510665,China)

机构地区：[1]前海人寿广州总医院呼吸科,广东广州511300 [2]中山大学附属第六医院,广东广州510665

出　　处：《今日药学》2022年第10期725-729,共5页Pharmacy Today

摘　　要：肺腺癌(lung adenocarcinoma, LUAD)是肺癌最常见的病理类型,因其存在分子靶向治疗所需的基因突变,分子靶向治疗成为了晚期肺腺癌患者的主要治疗方法之一。本文总结和归纳了近些年关于肺腺癌分子靶向治疗的应用研究和最新进展,旨在提高临床医师对分子靶向治疗的认识,为临床肺腺癌分子靶向治疗药物选择提供指导。Lung adenocarcinoma(LUAD) is the most common pathological type of lung cancer.Because of the gene mutations required by molecular targeted therapy, molecular targeted therapy has become one of the main treatments for patients with advanced lung adenocarcinoma.This article summarized the applied research and latest progress of molecular targeted therapy for lung adenocarcinoma in recent years, in order to improve clinicians’ understanding of molecular targeted therapy and provide guidance for clinical drug selection of molecular targeted therapy for lung adenocarcinoma.

关 键 词：肺腺癌 分子靶点 治疗 

分 类 号：R969[医药卫生—药理学]